Peripheral T-Cell Lymphoma Global Market Report 2025

The peripheral T-cell lymphoma market size has grown strongly in recent years. It will grow from 0.59 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increased awareness of rare lymphomas, the emergence of monoclonal antibodies, early orphan drug designations, advancements in hematologic cancer research, the growing adoption of stem cell transplants, improvements in diagnostic accuracy, the expansion of oncology healthcare infrastructure, and early innovations in immunotherapy.

The peripheral T-cell lymphoma market size is expected to see strong growth in the next few years. It will grow to $0.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in targeted therapies, the increasing adoption of personalized medicine, the expansion of immunotherapy applications, a robust pipeline of innovative drugs, rising healthcare investments in emerging markets, the growth of patient access programs, the integration of artificial intelligence in diagnostics, regulatory incentives for orphan drugs, and a growing focus on combination therapies. Key trends during this period include the development of novel biologics, advancements in gene editing technologies, the adoption of liquid biopsy diagnostics, AI-driven treatment planning, innovations in CAR-T cell therapy, progress in next-generation sequencing, the use of nanotechnology for drug delivery, personalized vaccine development, the emergence of bispecific antibodies, and automation in clinical trial processes.

The rising incidence of lymphoma is expected to drive the growth of the peripheral T-cell lymphoma (PTCL) market. Lymphoma is a type of cancer that originates in the lymphatic system, a key part of the body's immune system. The high occurrence of lymphoma is linked to genetic predisposition, environmental exposures, viral infections such as the Epstein-Barr virus, immunodeficiency conditions, and lifestyle factors such as smoking and obesity. Peripheral T-cell lymphoma contributes to lymphoma progression by arising from mature T-cells, leading to aggressive disease behavior, immune system dysfunction, and lower treatment responsiveness compared to other lymphoma subtypes. For example, according to the American Cancer Society's Facts and Figures, the estimated number of new non-Hodgkin lymphoma cases remained at 80,550 in both 2023 and 2024. As a result, the high incidence of lymphoma is fueling the expansion of the PTCL market.

Leading companies in the PTCL market are prioritizing the development of innovative treatments, such as dihydrofolate reductase inhibitors, to enhance treatment effectiveness and improve patient outcomes. These inhibitors work by blocking the activity of dihydrofolate reductase, an enzyme crucial for DNA synthesis and cell replication. For instance, in December 2024, Fresenius Kabi AG, a Germany-based pharmaceutical company, launched Pralatrexate Injection, a generic equivalent to Folotyn, for treating relapsed or refractory PTCL. This introduction expands the company’s oncology portfolio, offering clinicians and patients a high-quality, cost-effective treatment option. The injection is available in 20 mg/1 mL and 40 mg/2 mL single-dose vials and received accelerated approval based on overall response rate, with continued approval dependent on confirmatory trials.

In August 2024, Citius Pharmaceuticals Inc., a US-based pharmaceutical company specializing in treatments for relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL), merged with TenX Keane Acquisition to establish Citius Oncology Inc. This merger aims to create a standalone oncology-focused company, advancing the commercialization of Lymphir and expanding its oncology pipeline. TenX Keane Acquisition Corp. is a US-based company focused on raising capital through an initial public offering (IPO) to acquire or merge with an existing business.

Major players in the peripheral T-cell lymphoma market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Company Limited, BeiGene Ltd., Daiichi Sankyo Company Limited, HUYA Bioscience International LLC, Zymeworks Inc., Genor Biopharma Co. Ltd., Kura Oncology Inc., Acrotech Biopharma LLC, Spectrum Pharmaceuticals Inc., Verastem Inc., Astellas Pharma Inc., Autolus Therapeutics plc.

North America was the largest region in the peripheral T-cell lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peripheral T-cell lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peripheral T-cell lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Peripheral T-cell lymphoma (PTCL) is a group of aggressive non-Hodgkin lymphomas that develop from mature T-cells, a type of white blood cell crucial for immune function. PTCL can affect the lymph nodes, spleen, bone marrow, liver, and other organs, with symptoms including swollen lymph nodes, fever, night sweats, unexplained weight loss, skin rashes, and persistent fatigue.

The main types of PTCL include peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma, and other subtypes. PTCL-NOS is a cancer originating from mature T-cells that do not fit into specific classifications. Treatment options include chemotherapy, targeted therapy, immunotherapy, stem cell therapy, and radiation therapy. The drugs used are classified into histone deacetylase (HDAC) inhibitors, monoclonal antibodies, alkylating agents, antimetabolites, and other categories. These medications are administered through oral and injectable routes and are utilized by various end users, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

The peripheral T-cell lymphoma market research report is one of a series of new reports that provides peripheral T-cell lymphoma market statistics, including the peripheral T-cell lymphoma industry global market size, regional shares, competitors with the peripheral T-cell lymphoma market share, detailed peripheral T-cell lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the peripheral T-cell lymphoma industry. This peripheral T-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peripheral T-cell lymphoma market consists of revenues earned by entities by providing services such as diagnosis and screening services, treatment services, hospital and specialty care services, clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral T-cell lymphoma market also includes sales of corticosteroids, anthracyclines, vinca alkaloids, and topoisomerase inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.